The Goldilocks Zone of Type I IFNs: Lessons from Human Genetics
- PMID: 30530500
- DOI: 10.4049/jimmunol.1800764
The Goldilocks Zone of Type I IFNs: Lessons from Human Genetics
Erratum in
-
Correction: The Goldilocks Zone of Type I IFNs: Lessons from Human Genetics.J Immunol. 2019 Apr 15;202(8):2511. doi: 10.4049/jimmunol.1900253. Epub 2019 Mar 8. J Immunol. 2019. PMID: 30850478 No abstract available.
Abstract
Type I IFNs (IFN-Is) are powerful cytokines. They provide remarkable protection against viral infections, but their indiscriminate production causes severe self-inflicted damage that can be lethal, particularly in early development. In humans, inappropriately high IFN-I levels caused by defects in the regulatory mechanisms that control IFN-I production and response result in clinical conditions known as type I interferonopathies. In essence, type I interferonopathies define the upper limit of safe, IFN-related inflammation in vivo. Conversely, the loss of IFN-I responsiveness increases susceptibility to viral infections, but, surprisingly, most affected individuals survive despite these inborn errors of immunity. These findings suggest that too much IFN-I early in life is toxic, but that insensitivity to IFN-I is perhaps not the death sentence it was initially thought to be. Human genetic analyses have suggested that seemingly insignificant levels of IFN-regulated gene activity may be sufficient for most of the antiviral defenses used by humans in natura.
Copyright © 2018 by The American Association of Immunologists, Inc.
Similar articles
-
Interferon-omega: Current status in clinical applications.Int Immunopharmacol. 2017 Nov;52:253-260. doi: 10.1016/j.intimp.2017.08.028. Epub 2017 Oct 12. Int Immunopharmacol. 2017. PMID: 28957693 Free PMC article. Review.
-
Mechanisms of type III interferon expression.J Interferon Cytokine Res. 2010 Aug;30(8):573-8. doi: 10.1089/jir.2010.0063. J Interferon Cytokine Res. 2010. PMID: 20645874 Review.
-
Beyond Good and Evil: Molecular Mechanisms of Type I and III IFN Functions.J Immunol. 2022 Jan 15;208(2):247-256. doi: 10.4049/jimmunol.2100707. J Immunol. 2022. PMID: 35017214 Review.
-
Type III IFNs: Beyond antiviral protection.Semin Immunol. 2019 Jun;43:101303. doi: 10.1016/j.smim.2019.101303. Semin Immunol. 2019. PMID: 31771761 Free PMC article. Review.
-
What have we learned from the IL28 receptor knockout mouse?J Interferon Cytokine Res. 2010 Aug;30(8):579-84. doi: 10.1089/jir.2010.0061. J Interferon Cytokine Res. 2010. PMID: 20649452 Review.
Cited by
-
Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells.Nature. 2023 Mar;615(7951):305-314. doi: 10.1038/s41586-023-05736-y. Epub 2023 Feb 22. Nature. 2023. PMID: 36813963 Free PMC article.
-
Whole transcriptome analysis of high and low IFN-α producers reveals differential response patterns following rhinovirus stimulation.Clin Transl Immunology. 2021 Nov 17;10(11):e1356. doi: 10.1002/cti2.1356. eCollection 2021. Clin Transl Immunology. 2021. PMID: 34868584 Free PMC article.
-
Homozygous STAT2 gain-of-function mutation by loss of USP18 activity in a patient with type I interferonopathy.J Exp Med. 2020 May 4;217(5):e20192319. doi: 10.1084/jem.20192319. J Exp Med. 2020. PMID: 32092142 Free PMC article.
-
Autoantibodies in immunodeficiency syndromes: The Janus faces of immune dysregulation.Blood Rev. 2022 Sep;55:100948. doi: 10.1016/j.blre.2022.100948. Epub 2022 Mar 18. Blood Rev. 2022. PMID: 35428517 Free PMC article. Review.
-
Type I interferon regulation by USP18 is a key vulnerability in cancer.iScience. 2024 Mar 27;27(4):109593. doi: 10.1016/j.isci.2024.109593. eCollection 2024 Apr 19. iScience. 2024. PMID: 38632987 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical